

BHIVA conference speaker policy¹

Version control	Date and updates
Original	24 April 2023
Version 2	1 November 2023 Removed: <ul style="list-style-type: none"> ▪ A speaker invited by BHIVA to speak in a plenary session on a BHIVA conference programme cannot then be invited to speak in a pharmaceutical company sponsored session (to be added into BHIVA guidance to pharmaceutical companies when they sign up for a sponsored symposia). ▪ BHIVA Officers cannot accept an invitation to speak in a sponsored session at a BHIVA-organised conference. ▪ All other BHIVA committee members apart from the Officers, may accept an invitation to speak in a single sponsored session only – ensuring that they only speak on the scientific programme a max of twice (if also invited by BHIVA to speak).
Version 3	Due for review May–July 2024 ¹

- BHIVA Officers cannot accept an invitation to speak or chair in a pharmaceutical company sponsored session at a BHIVA-organised conference.
- All BHIVA Trustees, apart from the Officers, cannot accept a speaking or chairing role in a pharmaceutical company sponsored session, if they have been invited by BHIVA to speak in a plenary (unopposed) session already.
- A speaker invited by BHIVA to speak in a plenary (unopposed) session in a BHIVA conference programme cannot then be invited to speak or chair in a pharmaceutical company sponsored session.
- An invited chair or a BHIVA Trustee (not Officer), who is chairing a plenary (unopposed) session at a BHIVA conference, can participate in a pharmaceutical company sponsored session as a speaker or a chair.

¹ Process: 1. Conferences Subcommittee for comments (May meeting); 2. Executive Committee for comments (June meeting); 3. Officers for review and approval (July by email)